 |
| January
5, 2026 |
| Covering
Life Sciences Drugs, Diagnostics, Devices,
Digital Health |
|
|
|
* may need subscription to view |
 |
 |
| Boston's
most flexible contract vivarium
lab space: Start with a few study
cages and grow. |
|
Learn More
→ |
|
|
- Crescent Biopharma: Regulatory Clearances of
IND Applications for CR-001, a PD-1 x VEGF
Bispecific Antibody and CR-003, an
ITGB6-targeted ADC, for the Treatment of Solid
Tumors More
- Cogent Biosciences: Submission of New Drug
Application for Bezuclastinib in NonAdvanced
Systemic Mastocytosis More
- ElevateBio: Appoints Christopher Murphy
as Chief Executive Officer and Member of the
Board of Directors More
- HELUS Pharma: Propels Therapeutic Innovation
in Mental Health and Commences Trading on
Nasdaq More
- Kailera Therapeutics: Appoints Doug
Pagán as Chief Financial Officer More
- KreaMedica: New Ebook Offers
First-Time Biotech CEOs a Roadmap for the
Decisions That Determine Company Success More
- Neumora Therapeutics: Positive Results From
NMRA-511 Phase 1b Signal-Seeking Study in
Alzheimer’s Disease Agitation More
- Neumora Therapeutics: Highlights 2026
Pipeline Strategy and Anticipated Upcoming
Milestones More
- Nia Therapeutics: Publishes Peer-Reviewed
Validation of a 60-Channel Brain Implant for
Closed-Loop Neurostimulation More
- Orum Therapeutics: Appoints Chad May as
Chief Scientific Officer to Drive
Degrader-Antibody Conjugate Innovation and
Programs More
- Slone Partners: Places
Jeffrey Kasten as Chief Business Officer at
Vertero Therapeutics More
- Takeda and Protagonist: Submission of New
Drug Application (NDA) for Rusfertide for
Treatment of Polycythemia Vera (PV) More
- Tango Therapeutics: Appoints Sung Lee to
Board of Directors More
- Verastem Oncology: Update on RAMP 203 Phase
1/2 Clinical Trial for Advanced KRAS G12C
Mutant Non-Small Cell Lung Cancer More
More
More*
- Zenas BioPharma: Positive Results from Phase
3 INDIGO Registrational Trial of Obexelimab in
Immunoglobulin G4-Related Disease (IgG4-RD) More
|
|
 |
 |
The
Charles River CFO Advantage
Reassessing your business plan?
We provide financial leadership.
Smart. Nimble. Flexible. |
|
Learn More
→ |
|
|
|
- Aktis Oncology Eyes $181M Listing to
Start Industry’s Anticipated IPO Rebound More*
- Collegium: Closing of $980 Million
Syndicated Credit Facility More
- Exclusive: Comanche Collects $40M to Take
Preeclampsia siRNA Onto Global Stage More*
- Get Full Access to BYTE51 Life Sciences
Intelligence for 50% Off More
- Insilico Medicine: US$888 Million
Multi-Year Collaboration With Servier for
Drug Discovery and Development in Oncology More
More
More
More*
- Intellia Therapeutics: Inducement Grants
Under Nasdaq Listing Rule 5635(c)(4) More
- Ironwood Pharmaceuticals: FY 2025 Financial
Guidance and FY 2026 Financial Guidance More
More* More*
- JPM
Week Conference Readiness Packages (Big4Bio
Subscriber Discount) More
- Nido Bio to Wind Down After Underwhelming
Phase 2 Data More*
More
- Sarepta Therapeutics: Inducement Grants
Under Nasdaq Listing Rule 5635(c)(4) More
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
|
- Brain Health, Behavior, and the Future of
Dementia Prevention Podcast
- Former Gilead Exec Who Oversaw $20B in
Drug Sales Joins C-Suite of Boston Pharma
Giant More*
- Genetic Variant Appears to Protect Some
People Against Certain Blood Cancers More*
- Quanterix’s Blood Test for Alzheimer’s
Disease Uncovers Potentially Treatable
Population in Decades-Long Study More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
Feature your company |
| Apply
to have your company
showcased by Big4Bio |
|
|
|
|
|
 |
|
Premier Executive Search and
Talent Advisory Firm Slone
Partners Launches Fractional
Talent Service to Deliver
On-Demand Leaders and Specialists
|
|
Learn More
→ |
|
|
- AI in Biotech: The New Frontier for
Leadership & Strategy More
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- ICYMI: CEO’s Perspective: Big Moves Come
with Big Responsibility More
- ICYMI: CEO’s Perspective: The High Cost of
Job Hopping More
- ICYMI: Elevating Executive Presence: A
Blueprint for Life Sciences and Biotech
Leaders More
- ICYMI: The Power of Peer Learning - Why Even
Top Biotech Leaders Need Mentorship More
- ICYMI: What’s Next in Precision Medicine:
Leadership Challenges and Opportunities More
- The Rise of Fractional Talent in Life
Sciences: What to Expect in 2026 More
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
